INTRODUCTION {#S2}
============

Binge alcohol drinking is the most common form of excessive alcohol consumption and contributes to a host of long-term negative health consequences, including alcohol dependence and anxiety disorders^[@R5]--[@R9]^. Repeated bouts of binge-induced alcohol intoxication followed by withdrawal are hypothesized to cause aberrant plasticity in brain regions that underlie reward-seeking behavior and stress responsivity, leading to an increased negative affective state that drives increased alcohol consumption^[@R5],\ [@R9]--[@R11]^. These effects may be mediated by altered signaling of endogenous stress and anti-stress neuropeptide systems that functionally oppose each other, particularly corticotropin-releasing factor (CRF) and neuropeptide Y (NPY)^[@R10],\ [@R12]--[@R14]^. Central CRF signaling is recruited during binge alcohol drinking, enhances alcohol drinking and anxiety behavior, and is altered in rodent models of alcohol dependence^[@R15]--[@R18]^. In contrast, NPY signaling, primarily via its Y1 receptor (Y1R), blunts binge alcohol drinking and reduces anxiety^[@R10],\ [@R19]--[@R21]^; however the neural locus of these peptidergic effects is unknown. The bed nucleus of the stria terminalis (BNST) is a limbic brain structure enriched with CRF and NPY that is a site of integration of stress and reward information^[@R22],\ [@R23]^ and may mediate the negative affective state associated with chronic alcohol use. Pharmacological manipulations in the BNST can alter alcohol drinking behaviors^[@R24],\ [@R25]^ and chronic alcohol exposure and withdrawal alter the function and plasticity of BNST neurons^[@R26],\ [@R27]^, however the role of NPY signaling in the BNST to regulate alcohol drinking has not been evaluated.

RESULTS {#S3}
=======

Y1R activation in the BNST suppresses binge alcohol drinking {#S4}
------------------------------------------------------------

To begin to address these issues, we first examined how pharmacological manipulations of the NPY system in the BNST specific to signaling at its primary receptors, NPY--Y1 receptors (Y1R) and NPY--Y2 receptors (Y2R), alter binge alcohol drinking in C57BL/6J mice using the well-described "Drinking in the Dark" model of binge-like alcohol drinking^[@R28]^ ([Fig. 1a](#F1){ref-type="fig"}, [Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}). We used both agonists and antagonists to assess function associated with receptor activation and endogenous NPY tone, respectively ([Fig. 1](#F1){ref-type="fig"}, [Supplementary Figs. 1,2](#SD1){ref-type="supplementary-material"}). We found that infusion of a Y1R agonist into the BNST, but not adjacent dorsal striatum, reduced binge alcohol consumption ([Fig. 1b,c](#F1){ref-type="fig"}, [Supplementary Fig. 1b](#SD1){ref-type="supplementary-material"}, [Supplementary Fig. 2a](#SD2){ref-type="supplementary-material"}), while infusion of a Y1R antagonist into the BNST increased alcohol consumption ([Supplementary Fig. 1c,d](#SD1){ref-type="supplementary-material"}), consistent with our hypothesis that Y1R in the BNST is a neural substrate for NPY's anti-drinking effects. Interestingly, the effect of the Y1R antagonist did not emerge until the second half of the binge drinking session, suggesting that endogenous NPY signaling is recruited across the binge drinking session. Neither Y1R modulator in the BNST altered anxiety-like or locomotor behavior in the open field test (OF) or sucrose consumption ([Fig. 1d--f](#F1){ref-type="fig"}, [Supplementary Fig. 1e--g](#SD1){ref-type="supplementary-material"}, [Supplementary Fig. 2b](#SD2){ref-type="supplementary-material"}), suggesting that the behavioral effects of Y1R manipulation were specific to binge alcohol drinking. In contrast, intra-BNST infusion of the Y2R agonist increased alcohol consumption but decreased sucrose consumption without altering OF behavior ([Supplementary Fig. 1h--l](#SD1){ref-type="supplementary-material"}). Moreover, bilateral infusion of the Y2R antagonist had no measurable effects on behavior ([Supplementary Fig. 1m--q](#SD1){ref-type="supplementary-material"}; [Supplementary Fig. 2c,d](#SD2){ref-type="supplementary-material"}). These results suggest that manipulation of Y2R in the BNST may alter general reward-seeking/appetitive behaviors rather than binge alcohol drinking as Y1R does.

Mechanism of Y1R--mediated postsynaptic inhibition of BNST neurons {#S5}
------------------------------------------------------------------

We next investigated the synaptic mechanisms by which this specific Y1R-mediated suppression of alcohol drinking occurs using slice electrophysiology. We found that Y1R activation with the Y1R agonist enhanced the frequency of miniature inhibitory postsynaptic currents (mIPSCs) but not miniature excitatory postsynaptic currents ([Fig. 1g](#F1){ref-type="fig"}--**j**). This result suggested a presynaptic locus of Y1R potentially to directly increase GABA release from presynaptic terminals, in direct competition with the previously characterized function of presynaptic Y2R in the BNST of inhibiting presynaptic GABA release^[@R13]^. However, Y1R has typically been described as a postsynaptic G~i/o~-coupled receptor^[@R29],\ [@R30]^. Therefore to characterize the locus and mechanism of Y1R here in the BNST, we used selective inhibitors of canonical G protein-coupled receptor (GPCR) signaling pathways in the extracellular bath ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}) and directly in the postsynaptic neuron ([Fig. 1k](#F1){ref-type="fig"}). Disruption of G~s~/G~i~ signaling with bath application of the PKA inhibitor Rp-Adenosine 3′,5′--cyclic monophosphorothioate triethylammonium salt (Rp--cAMPs, 10 μM) blocked the ability of LeuPro NPY to increase mIPSC frequency, while disruption of the canonical G~q~ signaling pathway with the PLC inhibitor 1-\[6-\[\[(17β)-3-Methoxyestra-1,3,5(10)-trien-17-yl\]amino\]hexyl\]-1*H*-pyrrole-2,5-dione (U73122; 10 μM), did not ([Supplementary Fig. 3a](#SD1){ref-type="supplementary-material"}), providing evidence that Y1R is a G~i~-coupled receptor. However, additional experiments using postsynaptic-specific manipulations of GPCR signaling indicated that Y1R activation increased GABAergic transmission via a postsynaptic, protein kinase A (PKA)-dependent, mechanism. Inclusion of the non-hydrolyzable GDP analog guanosine 5′-\[β-thio\]diphosphate trilithium salt (GDPβS, 1 mM) to block postsynaptic GPCR activity, the vesicle fusion blocker and potent inhibitor of G~i~ signaling N-ethylmaleimide (NEM, 50 μM), and the PKA inhibitor fragment (6--22) amide (PKI, 20 μM) to inhibit PKA signaling in the recording pipette all blocked the ability of bath-applied LeuPro NPY to increase mIPSC frequency, while the calcium chelator 1,2-Bis(2-aminophenoxy)ethane-*N*,*N*,*N*′,*N*′-tetraacetic acid (BAPTA, 10 μM) did not ([Fig. 1k](#F1){ref-type="fig"}). Analysis of basal mIPSC frequency in these experiments suggests that the ability of the Y1R agonist to increase mIPSC frequency was independent of basal frequency ([Supplementary Fig. 3b](#SD1){ref-type="supplementary-material"}).

Because activation of postsynaptic Y1R non-canonically increased mIPSC frequency, rather than amplitude, we evaluated the possible mechanisms of this effect, including alterations in postsynaptic excitability, activation of a retrograde signal to enhance presynaptic GABA release, and modulation of postsynaptic GABA receptor function. Analysis of membrane resistance during mIPSC experiments suggested that Y1R activation did not change cell membrane conductance ([Supplementary Fig. 3c](#SD1){ref-type="supplementary-material"}). Further, Because Cs can block K^+^ channels, we also evaluated the effect of LeuPro NPY on mIPSCs using a Cs-based intracellular solution in the recording pipette rather than a K^+^-based solution. We found a similar effect of the Y1R agonist on mIPSC frequency (20.2 ± 6.4%), suggesting that Y1R activation was not altering the conductance of dendritic potassium channels ([Supplementary Fig. 3d](#SD1){ref-type="supplementary-material"}). Next, we examined whether Y1R activates a retrograde messenger or alters postsynaptic GABA receptor function. Y1R activation enhanced IPSCs mediated by super-physiological exogenous application of GABA (100 μM) directly to the postsynaptic neuron, which was ablated by a GABA~A~R antagonist ([Fig. 1l](#F1){ref-type="fig"}), demonstrating that Y1R modulation of postsynaptic GABA responses was present when presynaptic GABA release was occluded and suggesting that the Y1R effect was not via activation of a retrograde signal but via enhancement of postsynaptic GABA~A~R function. Further, blocking postsynaptic fusion of newly-trafficked postsynaptic GABA~A~Rs to the membrane with the intracellular inhibitor of protein transport to the Golgi apparatus brefeldin A (BFA, 200 nM) prevented the effect of the Y1R agonist on mIPSC frequency, while blocking endocytosis of postsynaptic GABA~A~Rs with dynamin inhibitory peptide (DIP, 2mM; [Fig. 1k](#F1){ref-type="fig"}) had no effect. Together, these results suggest that in the BNST, Y1R is a postsynaptic G~i~-coupled GPCR that increases the surface expression of postsynaptic GABA~A~Rs by inhibiting PKA activity, a previously undescribed mechanism of inhibitory plasticity.

Receptor-specific circadian regulation of endogenous NPY signaling {#S6}
------------------------------------------------------------------

Because C57BL/6J mice are nocturnal and binge drink during the dark phase of the light cycle^[@R18],\ [@R31]^, we next tested the hypothesis that chronic binge alcohol drinking disrupts NPY signaling in the BNST. While endogenous NPY levels and function have been shown to fluctuate across the light cycle in many brain regions^[@R32]^, we found that there were no circadian oscillations in NPY levels or basal GABAergic transmission in the BNST ([Fig. 2a--d](#F2){ref-type="fig"}). However, NPY modulation of GABAergic transmission was different across the light cycle ([Fig. 2e--f](#F2){ref-type="fig"}). Both the Y1R and Y2R agonists altered mIPSC frequency, but not amplitude, during the light phase of the light cycle but not the dark phase ([Fig. 2c](#F2){ref-type="fig"}). Pre-application of a Y1R antagonist blocked the effect of subsequently-applied Y1R agonist (p \> 0.90), but not the Y2R agonist (t(4) = 3.32, p = 0.029), confirming the receptor specificity of the Y1R-mediated effect (data not shown). Interestingly, the Y1R antagonist did not modulate GABAergic transmission during either phase of the light cycle, but the Y2R agonist increased mIPSC frequency during the dark phase, but not light phase, of the light cycle ([Fig. 2f](#F2){ref-type="fig"}). Circadian regulation of Y2R antagonist effects on GABAergic transmission during suggests that NPY receptors may be more highly expressed or functionally upregulated during the dark phase, leading to greater endogenous receptor-mediated NPY tone that may occlude the effects of exogenously applied NPY agonists. The inability of the Y1R antagonist to alter GABAergic transmission during the dark phase may be due to more rapid desensitization of Y1R compared to Y2R^[@R33]^. Furthermore, increased NPY tone during the dark phase may be related to circadian regulation of binge ethanol drinking. Altogether, these results suggest that there is greater NPY receptor expression and receptor-mediated endogenous NPY tone during the dark phase of the cycle, when mice binge drink alcohol.

Chronic binge drinking alters circadian regulation of Y1R function {#S7}
------------------------------------------------------------------

We tested the hypothesis that circadian regulation in receptor-specific NPY function in the BNST may be important for Y1R modulation of binge alcohol drinking and that the negative behavioral consequences of chronic binge drinking may be mediated by loss of circadian control of Y1R-mediated NPY signaling in the BNST. One day after three cycles of binge drinking in the DID paradigm ([Fig. 3a](#F3){ref-type="fig"}, [Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}), BNST neurons of mice that drank ethanol (EtOH) had greater basal spontaneous IPSC frequency, but not amplitude, than those of water-drinking controls (CON), while mIPSC frequency and amplitude were not different between groups ([Fig. 3b](#F3){ref-type="fig"}). As observed in experiments with naïve mice ([Fig. 2](#F2){ref-type="fig"}), Y1R and Y2R agonists did not modulate GABAergic transmission in BNST neurons of CONs during the dark phase of the light cycle; however, they did in EtOH mice ([Fig. 3c--d](#F3){ref-type="fig"}). In addition, Y1R modulation of inhibitory synaptic transmission in 3-cycle EtOH mice could be blocked by intracellular inclusion of a PKA inhibitor ([Fig. 3k](#F3){ref-type="fig"}), suggesting an upregulation of the Y1R mechanism characterized above. Consistent with these effects, both Y1R and Y2R protein expression, but surprisingly not NPY expression, were greater in the BNST of EtOH mice than CONs at this time point ([Fig. 3e--g](#F3){ref-type="fig"}). Because there was no alteration in the mRNA of NPY, Y1R, or Y2R ([Supplementary Fig. 4b--d](#SD1){ref-type="supplementary-material"}), this increase in receptor protein expression and function following chronic binge alcohol drinking is likely translation-dependent. Interestingly, NPY protein expression was decreased immediately following the last binge ethanol session of either 1-cycle or 3-cycle EtOH DID compared to CONs ([Fig. 3h](#F3){ref-type="fig"}), suggesting that the endogenous NPY system is acutely recruited during each binge ethanol drinking session. In order to determine whether increased Y1R function following 3-cycle DID was merely an acute response to this NPY recruitment and depletion that occurs during each binge ethanol drinking session or whether it requires repeated cycles of binge drinking and withdrawal, we also examined Y1R modulation of inhibitory synaptic transmission one day after 1-cycle DID. We found that Y1R activation with LeuPro NPY did not alter GABAergic transmission after a single cycle of DID ([Fig. 3k](#F3){ref-type="fig"}) as it did after three cycles, suggesting that the upregulation of Y1R function may be an adaptive response that develops across repeated cycles of binge drinking to compensate for the allostatic burden imposed on the mice from repeated acute recruitment and depletion of NPY that occurs with each binge drinking episode. Further, the enhancement of Y1R function observed after three cycles of binge drinking persisted up to 10 days following the final binge drinking episode ([Fig. 3k](#F3){ref-type="fig"}), suggesting that this was a long-lasting change in function of the NPY system. To determine the translational potential of these findings, we also investigated how chronic alcohol drinking in non-human primates alters Y1R signaling in the BNST using a well-established model of voluntary, long-term ethanol self-administration in adult male rhesus macaques^[@R34]^ ([Fig. 3i](#F3){ref-type="fig"}). Consistent with mouse experiments, Y1R activation with LeuPro NPY increased GABAergic transmission in BNST neurons of chronic binge-drinking, but not control monkeys ([Fig. 3j,k](#F3){ref-type="fig"}). Together, these data show that dysregulation of Y1R--mediated endogenous NPY signaling in the BNST is an enduring effect of chronic alcohol use that develops prior to physical dependence but persists during long-term binge alcohol drinking and across mammalian species.

Postsynaptic modulation by Y1R in the BNST is specific to CRF neurons {#S8}
---------------------------------------------------------------------

When we examined the effect of Y1R activation on GABAergic transmission in the BNST of naïve mice, we noted a considerable amount of variability in the magnitude of the effect across individual neurons, which has also been reported in the basolateral amygdala^[@R29]^. Because CRF has been shown to increase alcohol drinking in mice^[@R16],\ [@R35]^, the opposite phenotype that we found with Y1R activation in the BNST, and both peptides are densely expressed in the BNST^[@R13],\ [@R36]^, we hypothesized that Y1R activation in the BNST decreases binge alcohol drinking by directly inhibiting CRF neurons. We first evaluated the ability of Y1R activation to alter synaptic function at CRF neuron synapses using slice electrophysiology in the BNST of CRF-reporter mice ([Fig. 4a,b](#F4){ref-type="fig"}). CRF+ neurons had greater mIPSC amplitude, but not frequency, than CRF− neurons ([Fig. 4c,d](#F4){ref-type="fig"}). Y1R activation with bath application of LeuPro NPY greatly increased mIPSC frequency in CRF+ neurons by 54.7 ± 19.3% but did not alter mIPSC frequency in CRF− neurons (−1.3 ± 7.8%; [Fig. 4e](#F4){ref-type="fig"}), suggesting that the effects of Y1R in the BNST are specific to CRF neurons. Further, LeuPro NPY decreased the amplitude of mIPSCs in CRF+, but not CRF−, neurons by a small but significant amount ([Fig. 4f](#F4){ref-type="fig"}) and increased the decay time of mIPSC events in CRF+ neurons but not CRF− neurons ([Fig. 4g](#F4){ref-type="fig"}). Analysis of the cumulative probability distribution of mIPSC events confirmed that Y1R activation led to an increase in smaller-amplitude mIPSCs in CRF+ but not CRF− neurons ([Fig. 4h](#F4){ref-type="fig"}). Together, results suggest that activation of postsynaptic Y1R on CRF neurons in the BNST results in the insertion of GABA~A~Rs with longer decay kinetics, such as those with α~2/3~ subunits, leading to more smaller-amplitude IPSCs with longer decay.

Direct *in vivo* chemogenetic activation of G~i~ signaling in BNST CRF neurons suppresses binge drinking {#S9}
--------------------------------------------------------------------------------------------------------

Our results indicate that G~i~-coupled Y1Rs may be specifically expressed postsynaptically on CRF neurons in the BNST, where they function to decrease binge alcohol drinking by enhancing synaptic inhibition of CRF neurons (depicted in the model in [Supplementary Fig. 5a](#SD1){ref-type="supplementary-material"}). We directly tested this hypothesis by evaluating whether *in vivo* activation of G~i~ signaling in CRF neurons in the BNST decreases binge alcohol consumption. We injected the BNST of *CRF-ires-Cre* (*CRF-Cre*) knock-in mice backcrossed to a C57BL/6J background with either a virus containing a Cre-dependent G~i~-coupled designer receptor activated by designer drug (G~i~-DREADD) or a control vector^[@R37]^ ([Fig. 5a,b](#F5){ref-type="fig"}). Selective chemogenetic activation of the G~i~-DREADD with bath application of the designer drug *clozapine-N-oxide* (CNO) during slice electrophysiology recordings hyperpolarized G~i~-DREADD-expressing *CRF-Cre* neurons in the BNST, confirming that this manipulation functionally inhibits *CRF-Cre* neurons ([Supplementary Fig. 5b,c](#SD1){ref-type="supplementary-material"}). *In vivo* systemic administration of CNO prior to ethanol access on Day 4 Cycle 3 of DID suppressed binge alcohol consumption in G~i~-DREADD mice but not control vector (CON) mice ([Fig. 5c](#F5){ref-type="fig"}), recapitulating the effect of Y1R activation in the BNST ([Fig. 1b](#F1){ref-type="fig"}). Intriguingly, CNO injection before OF decreased anxiety-like behavior in G~i~-DREADD mice but not CONs ([Fig. 5d](#F5){ref-type="fig"}) without altering locomotor behavior ([Fig. 5e](#F5){ref-type="fig"}), altogether suggesting that alterations in binge alcohol drinking and anxiety by manipulation of G~i~ signaling in CRF neurons were not due to non-specific locomotor effects of CNO.

Because *in vivo* inhibition of PKA via activation of G~i~ signaling in BNST CRF neurons reduced binge drinking and anxiety, we also tested whether stimulation of PKA via activation of G~s~ signaling was sufficient to increase the expression of these behaviors using an identical experimental procedure as for G~i~ signaling ([Fig. 5f,g](#F5){ref-type="fig"}). CNO administration did not alter binge alcohol drinking or OF behavior in mice with the G~s~-DREADD or CON vector ([Fig. 5h--j](#F5){ref-type="fig"}). However, when mice received both CNO and intra-BNST infusion of the Y1R agonist LeuPro NPY on a subsequent cycle of binge drinking, activation of the G~s~-DREADD blocked the ability of the Y1R agonist to suppress binge alcohol drinking ([Fig. 5k](#F5){ref-type="fig"}). This suggests that stimulation of PKA in BNST CRF neurons via G~s~ activation is sufficient to block the PKA-inhibiting mechanism by which Y1R activation regulates binge drinking. This finding provides further *in vivo* evidence that the mechanism of Y1R-mediated inhibition of BNST CRF neurons we characterized using *ex vivo* electrophysiology is the mechanism by which Y1R suppresses binge alcohol drinking.

DISCUSSION {#S10}
==========

This is the first report to provide direct evidence that NPY signaling and CRF neurons in the BNST are involved in the regulation of binge alcohol drinking. Many previous reports have demonstrated that NPY and CRF produce divergent alcohol-drinking phenotypes^[@R20],\ [@R35]^, and our data suggest that this may be due to their opposing functional roles in the BNST. Further, the anti-drinking effects of NPY are produced by its direct inhibition of BNST CRF neurons via Y1R, suggesting a specific anatomical and synaptic locus for the interaction between these two peptides. Interestingly, a role for postsynaptic Y1R-mediated inhibition has also recently been reported for the basolateral amygdala^[@R29]^, where it is involved in reducing anxiety. However, here we found a novel, non-canonical postsynaptic mechanism by which Y1R activation increased the frequency of postsynaptic inhibitory currents, suggesting that Y1R signaling potentiates postsynaptic GABA~A~R responses, altering plasticity at inhibitory synapses on CRF neurons in the BNST. Given the extensive literature describing the roles of GABARs and CRF in alcohol drinking and dependence^[@R16],\ [@R18],\ [@R35],\ [@R38]--[@R43]^, strict modulation of the function and plasticity of GABARs on CRF neurons in the BNST by Y1R may be particularly important for maintaining homeostasis of CRF neuronal activity. Thus, alterations of normal NPY function, such as those after chronic binge alcohol drinking, may have profound consequences on long-term behavioral outcomes, including continued alcohol use that leads to dependence.

We found that the endogenous NPY system was acutely recruited across each binge alcohol drinking session and that as few as three cycles of binge alcohol drinking in rodents, before the development of alcohol dependence^[@R44]^, drastically and chronically altered the NPY system in the BNST for at least 10 days after the last binge episode. We observed the same adaptation of Y1R in the BNST of long-term alcohol-drinking rhesus monkeys, suggesting that this adaptation is a common adaptation across voluntary ethanol administration paradigms, states of alcohol dependence, and species. This is supported by pharmacological and genetic studies that implicate the regulation of NPY in alcohol dependence^[@R1],\ [@R3],\ [@R20],\ [@R21],\ [@R45],\ [@R46]^. The persistence of this widely-observed consequence of binge alcohol drinking suggests that Y1R, or more broadly, inhibition of CRF neuron function, may be an effective pharmacotherapeutic target for the prevention and treatment of alcohol abuse.

ONLINE METHODS {#S11}
==============

Subjects {#S12}
--------

Adult male C57BL/6J mice acquired from Jackson Laboratory (Bar Harbor, ME) were six weeks old at beginning of the study. *CRF-ires-Cre* (*CRF-Cre*, also termed *CRH-ires-Cre*) mice were generated using bacterial artificial chromosome (BAC) recombineering techniques as described previously^[@R47]^. Briefly, an optimized internal ribosome entry sequence fused with a Cre transgene and FRT-flanked neomycin resistance cassette was targeted three bases after the stop codon of the *CRF* gene contained in a BAC. The final targeting construct contained approximately 4kb of flanking sequence on either side of the Cre cassette. Following electroporation into ES cells, positive clones were identified by long range PCR and confirmed by southern blotting. Appropriately targeted ES cells were injected into blastocysts and chimeric animals were generated by the Beth Israel Deaconess Transgenic core. Germline transmission of the targeted transgene was confirmed by PCR of tail DNA using the following primer sequences: CRFstopF2: GATCTCACCTTCCACCTTCTG, CRHstopR2: CAAAGGTTTCCTCCTTGGGG and iresR2: CACACCGGCCTTATTCCAAGC. After confirming germline transmission, the CRF*--ires--Cre* mice were crossed to a *Rosa26--Flpe* deleter mouse (JAX stock 003946) to delete the Frt--flanked neo cassette. Deletion of the neo cassette was confirmed by PCR. *CRF-Cre* mice were backcrossed onto a C57BL/6J strain in order to maintain consistency with experiments performed in wildtype mice. For some electrophysiology experiments, *CRF-Cre* mice were crossed with floxed Ai3 (CAGFloxed EYFP) or floxed Ai9 (CAG-Floxed tdTomato) mice acquired from Jackson Laboratory (Bar Harbor, ME) to allow *a priori* identification of CRF neurons with fluorescent proteins.

Mice used for signaling and reverse light cycle studies were group-housed, and mice in drinking experiments were singly-housed, in colony rooms with 12:12 hr light-dark cycle with lights on at 7 a.m. or 7 p.m. Mice had *ad libitum* access to rodent chow and water. All procedures were approved by the Institutional Animal Care and Use Committee of the University of North Carolina at Chapel Hill and performed in accordance with the National Institutes of Health guide for the care and use of laboratory animals.

Drinking in the Dark experiments {#S13}
--------------------------------

We used the four-day Drinking in the Dark procedure (DID; [Fig. 1a](#F1){ref-type="fig"}, [Supplementary Fig. 1a](#SD1){ref-type="supplementary-material"}), which is a well-established animal model of human binge drinking that generates high ethanol intake and blood ethanol concentrations (≥80 mg/dl) and has been used to characterize neuromodulators of binge-like alcohol consumption^[@R18],\ [@R35]^. Three h into the dark cycle, water bottles were replaced with bottles containing a 20% (v/v) ethanol solution for 2 h on Days 1--3 and 4 h on Day 4. For all experiments involving multiple cycles of DID procedures, each cycle was separated by 3 d of abstinence.

First, we examined whether bilateral intra-BNST administration of the following selective NPY receptor modulators could decrease binge alcohol drinking in four distinct experiments using separate cohorts of mice ([Fig. 1a](#F1){ref-type="fig"}): Y1R agonist \[Leu^31^Pro^34^\]--Neuropeptide Y (LeuPro NPY; 99 pmol/200 nL/side), Y1R antagonist BIBP 3226 (20 pmol/200 nL/side), Y2R agonist NPY 13--36 (100 pmol/200 nL/side), and Y2R antagonist BIIE 0246 (120 pmol/200 nL/side). First, mice underwent one cycle of DID to establish baseline binge drinking levels. Then mice were implanted with cannulae aimed at the dorsal BNST (with respect to Bregma -- AP: +0.3 mm, ML: ±1.1 mm, DV: −4.35 mm) under an anesthetic cocktail of ketamine (110μmg/kg) and xylazine (10μmg/kg), with the aid of the Leica Angle Two stereotaxic instrument (Leica Microsystems Inc, Buffalo Grove, IL). After 10 d of recovery from surgery and habituation to the head caps, mice underwent Cycles 2 and 3 of DID. For all four experiments, mice received bilateral intra-BNST injections of vehicle (10% DMSO in sterile water (sH~2~0) or in 0.9% saline, depending on compound administered on Cycle 3 challenge) two hr before ethanol access on the fourth, binge test day of Cycle 2 using a 33--gauge micro-injection needle (Hamilton Company, Reno, NV) at a rate of 100nL/min. The micro-injection needle was left in place for one min post-infusion to allow for adequate diffusion of the drug away from the injector tip. On Day 4 Cycle 3, mice received intra-BNST infusions of LeuPro NPY or sH~2~0 vehicle (Experiment 1), BIBP 3226 or sH~2~0 vehicle (Experiment 2), NPY 13--36 or saline vehicle (Experiment 3), and BIIE 0246 or sH~2~0 vehicle (Experiment 4). Placement into the drug or control group was determined in a pseudo-random fashion so that the two groups had similar means and SEM for baseline ethanol drinking. Ten days after DID, mice within the cohort received the opposite infusion solution before the open field test (OF). Ten days later, mice underwent a cycle of DID with 10% sucrose instead of ethanol, and they were randomly assigned within the cohort to receive drug or vehicle. Experiments were replicated for LeuPro NPY and BIIE 0246 after 2--cycle DID in separate cohorts of mice ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}).

Experiments to examine the effect of direct *in vivo* activation of G~i~ or G~s~ signaling in BNST CRF neurons were conducted similarly ([Fig. 5a,f](#F5){ref-type="fig"}) but used both male and female *CRF-Cre* mice. Because effects were always present in either both or neither sex, and no differences were observed between sexes, mice were combined for all data presented. After one cycle of DID, *CRF-Cre* mice received intra-BNST (with respect to Bregma -- AP: +0.3 mm, ML: ±1.1 mm, DV: −4.35 mm) microinjections of a virus containing a Cre-dependent G~i~-coupled designer receptor activated by designer drug (G~i~-DREADD), AAV8-hSyn-DIO-hM4D-mCherry, or a control vector, AAV8-hSyn-DIO-mCherry, under an anesthetic cocktail of ketamine (100μmg/kg) and xylazine (10μmg/kg). Virus was infused at a rate of 100nL/min for 5 min (400--500 nL total volume each side), and microinjection needles were left in place for 10 min post-infusion. After \~10 d recovery, mice underwent a second cycle of DID with NaCl (saline) injections (0.9%, i.p. on Days 1--3, plus 0.5% DMSO on Day 4) administered 40 min before ethanol access each day. On the next cycle of DID, mice were administered clozapine N-oxide (CNO; 3 mg/kg, i.p on Day 4), the selective DREADD agonist, instead of vehicle, before ethanol access on the fourth day. Thus, CNO was not delivered until the DREADD virus had been in the BNST for at least three weeks to allow for maximal transduction of the viral vector and incorporation and expression of the DREADD receptors^[@R37]^. Two weeks later, mice were given CNO (3 mg/kg, i.p.) immediately before an open field test. Because CNO activation of the DREADD requires approximately 40 min, the first 40 min of OF was used as a baseline to compare to behavior during the activated DREADD. A similar experiment was carried out for examination of G~s~ signaling in BNST CRF neurons using a G~s~-coupled DREADD virus (AAV8-hSyn-DIO-rM3D-mCherry; G~s~-DREADD) or control mCherry vector. Mice in the G~s~-DREADD experiment were subsequently bilaterally cannulated in the BNST and then they underwent an additional cycle of EtOH DID. On the binge test day, mice received CNO (3 mg/kg, i.p.) 180 min prior to ethanol access, LeuPro NPY (99pmol/200nL/side, inta-BNST) 140 min prior to ethanol access, and a CNO booster (3 mg/kg, i.p.) 40 min prior to ethanol access. For *in vivo* pharmacology and DREADD experiments described above, mice were sacrificed following the last behavior and cannulae and virus injection placements were histologically verified (shown for DREADDs in [Fig. 5b,g](#F5){ref-type="fig"}). Only mice with bilateral hits were included in data analysis, leading to exclusion of 0--4 mice per group across all experiments, except for the G~s~-DREADD + LeuPro NPY experiment in which mice that had unilateral cannulae hits were included (n=2/group).

To examine the effects of binge alcohol drinking on the NPY system in the BNST, mice underwent one or three cycles of DID and were then sacrificed immediately, one day, or 10 d after the last binge session for electrophysiology, immunohistochemistry, or RT-PCR. Mice consumed 6.4--7.2 g/kg on the binge ethanol test day across the three cycles, with corresponding high blood ethanol concentrations (BECs) of 162 mg/dl immediately following the Cycle 3 binge session ([Supplementary Fig. 4a](#SD1){ref-type="supplementary-material"}). This 3--cycle DID procedure has been shown to increase alcohol preference in a two-bottle choice paradigm without inducing alcohol dependence^[@R44]^

Ethanol self-administration in rhesus monkeys {#S14}
---------------------------------------------

We used schedule-induced polydipsia to induce voluntary, long-term ethanol self-administration (ESA) in adult male rhesus monkeys (*Macaca mulatta)*, as previously described^[@R34],\ [@R48]^. Briefly, monkeys were individually housed in stainless steel cages that allowed for visual, auditory, and olfactory sensory contact with each other in a colony room with 12:12 hr light-dark cycle with lights on at 7 a.m. Monkeys were trained to use operant panels in their cages that supplied all food, water, and ethanol, and all panel data were recorded with a National Instruments interface (Austin, TX). Then monkeys were trained daily to use the panel and induced to drink 0.0, 0.5, 1.0, and 1.5 g/kg ethanol (4%) in 30 d epochs. Monkeys were subsequently allowed to voluntarily administer 4% ethanol and water *ad libitum* for 22 h/d, 7 d/wk for 12 calendar months before necropsy (at 5.5--8 yrs old). Daily average ethanol intake across monkeys ranged from 1.7 to 2.8 g/kg.

Reverse light cycle signaling experiments {#S15}
-----------------------------------------

To examine circadian oscillations in NPY signaling in the BNST, C57BL/6J mice were sacrificed approximately three hr after lights on or lights off in the colony room, and their brains were harvested for electrophysiology or immunohistochemistry experiments. This timing was consistent with all other experiments performed in the current study and with characterized timing of circadian fluctuations in NPY signaling in the hypothalamus^[@R32]^. Group assignment was random.

Slice electrophysiology {#S16}
-----------------------

We performed whole-cell voltage-clamp electrophysiological recordings in BNST neurons from acutely-prepared coronal brain slices of C57BL/6J mice, *CRF-Cre* reporter mice, and rhesus monkeys as previously described^[@R36]^ to examine the effects of NPY modulators on synaptic transmission in the BNST, with experimenters blind to experimental condition. Mice were decapitated under isoflurane anesthesia, and their brains were rapidly removed and placed in ice-cold sucrose-artificial cerebrospinal fluid (aCSF) containing (in mM) 194 sucrose, 20 NaCl, 4.4 KCl, 2 CaCl~2~, 1 MgCl~2~, 1.2 NaH~2~PO~4~, 10.0 glucose, and 26.0 NaHCO~3~ saturated with 95% O~2~/5% CO~2~. Coronal slices 300 μm in thickness containing the dorsal BNST (Bregma 0.26--0.02 mm) were sectioned on a Leica VT1200 vibratome and stored in a holding chamber of 28--30°C, oxygenated ACSF containing (in mM) 124 NaCl, 4.4 KCl, 2 CaCl~2~, 1.2 MgSO~4~, 1 NaH~2~PO~4~, 10.0 glucose, and 26.0 NaHCO~3~. Slices were transferred to a submerged recording chamber (Warner Instruments, Hamden, CT), where they were perfused with heated, oxygenated aCSF at a rate of approximately 2 ml/min and allowed to equilibrate for 30 min before electrophysiological recordings. For recordings in *CRF* x Ai3 mice, *CRF-Cre-*positive neurons were excited by a 490 nm LED and visualized under a 40× immersed objective with GFP filter.

Neurons were held at −70 mV across all voltage-clamp recordings. GABA~A~ receptor (GABA~A~R)-mediated inhibitory postsynaptic currents (IPSCs) were pharmacologically isolated during recordings by adding kynurenic acid (3 mM) to the bath solution to block AMPA and NMDA receptor-dependent postsynaptic currents. Recording electrodes were filled with (in mM) 70 KCl, 65 K^+^--gluconate, 5 NaCl, 10 HEPES, 2 QX-314, 0.6 EGTA, 4 Na-ATP, 0.4 Na-GTP, pH 7.25, 290--295 mOsmol. Glutamatergic excitatory postsynaptic currents (EPSCs) were isolated by adding picrotoxin (25 μM) to the bath solution to block GABA~A~R-mediated currents. Recording electrodes were filled with (in mM) 117 gluconic acid, 20 HEPES, 0.4 EGTA, 5 TEA, 2 MgCl2, 2 QX-314, 4 Na-ATP, 0.4 Na-GTP, pH 7.3, 290--295 mOsmol. Miniature IPSCs and EPSCs were isolated by including tetrodotoxin (500 nM) in the bath solution. For experiments examining the effects of LeuPro NPY on exogenously-applied GABA, kynurenic acid (3 mM) was included in the extracellular solution and delivery of GABA (100 μM) was directly administered to the synapse with a picospritzer. Experiments to functionally confirm DREADDs were performed in current-clamp configuration using a KGluc-based intracellular solution containing (in mM) 135 K-Gluc, 5 NaCl, 2 MgCl^2^, 10 HEPES, 0.6 EGTA, 4 Na-ATP, and 0.4 Na--GTP. Signals were acquired via a Multiclamp 700B amplifier and analyzed using Clampfit 10.3 software (Molecular Devices, Sunnyvale, CA). Bath-applied drugs were diluted in bath aCSF from stocked frozen aliquots, and intracellular drugs were diluted to working concentrations directly in the intracellular recording solution. Cells were allowed to equilibrate to the recording pipette and intracellular solution for at least 30 min before recordings began. Input resistance and access resistance were continuously monitored during all experiments, and those in which changes in access resistance were greater than 20% were not included in the data analysis.

Drugs and viral vectors {#S17}
-----------------------

The following drugs used in microinfusion and electrophysiology experiments were obtained from Tocris/R&D Biosystems (Minneapolis, MN): \[Leu31Pro34\] ---Neuropeptide Y (LeuPro NPY), Neuropeptide Y 13--36 (NPY 13--36), BIIE 0246, BIBP 3226 trifluoroacetate, 1-\[6-\[\[(17β)-3-Methoxyestra-1,3,5(10)-trien-17-yl\]amino\]hexyl\]-1*H*-pyrrole-2,5-dione (U73122), guanosine 5′-\[β-thio\]diphosphate trilithium salt (GDPβS), PKA inhibitor fragment (6--22) amide (PKI), 1,2--bis(o--aminophenoxy)ethane--N,N,N′,N′-tetraacetic acid (BAPTA), and dynamin inhibitory peptide (DIP). The following drugs were obtained from Abcam (formerly Ascent; Cambridge, UK): NPY 13--36, SR95531 (GABAzine), kynurenic acid sodium salt, picrotoxin, tetrodotoxin citrate (TTX), and GABA. The following drugs were obtained from Sigma--Aldrich (St. Louis, MO): Rp-Adenosine 3′,5′--cyclic monophosphorothioate triethylammonium salt (Rp--cAMPs), Protein Kinase A Catalytic Subunit from bovine heart (cPKA), and lidocaine *N*--ethyl bromide. *N*-Ethylmaleimide (NEM) was obtained from Fisher Scientific (Waltham, MA), and Brefeldin A was purchased from Cell Signaling Technology, Inc. (Danvers, MA). The viral vectors AAV8-hSyn-DIO-hM4D(G~i~)-mCherry (G~i~-DREADD), AAV8-hSyn-DIO-rM4D(G~s~)-mCherry (G~s~-DREADD), and AAV8-hSyn-DIO-mCherry (control vector), which have been described elsewhere^[@R37]^, were obtained from the UNC Viral Vector Core. CNO was kindly given to us by Bryan Roth.

RT-PCR {#S18}
------

We examined the expression of NPY, Y1R, and Y2R mRNA one day after the last binge ethanol drinking session using RT--PCR, with experimenters blind to experimental condition of the subjects, which were randomly assigned. Mice were anesthetized with isoflurane and decapitated. Brains were rapidly excised using ice-cold sterilized tools and immersed in ice-cold sterile RNase-free water. Brains were rapidly blocked into 1 mm coronal sections and frozen over dry ice. Bilateral punches of the BNST one mm in diameter were taken for each mouse and combined to provide one sample per mouse. Samples were stored at −20 °C in RNA*later* RNA stabilization reagent (Qiagen, Germantown, MD) until being processed by the UNC Genomics core. Cycle threshold (CT, the number of cycles required for the fluorescent signal to cross a set threshold) was determined for the reference gene, β-actin, and the target gene. Relative expression (RE) for each target gene was calculated from the following equation and then averaged across samples within each group: RE = 2^−\ (Ct\ target\ gene\ −\ Ct\ reference\ gene)^

Immunohistochemistry {#S19}
--------------------

Mice were anesthetized with Avertin and then perfused intracardially with 0.01M phosphate buffer saline (PBS) followed by 4% paraformaldehyde (PFA) in PBS. Brains were extracted and post-fixed for 24 hours in 4% PFA, then rinsed twice with PBS and put in 30% sucrose until saturated. Brains were hemisected and coronal slices 45 μm in thickness containing the BNST were prepared using a Leica VT1200 vibratome (Leica Microsystems, Nussloch, Germany) for immunohistochemistry for NPY, Y1R, and Y2R. Specificity of all three antibodies have previously been established: the NPY antibody was verified with colocalization of green fluorescent protein (GFP) and NPY (\>95%) in NPY-sappphire-GFP transgenic mice^[@R49]^, and the Y1R^[@R30]^ and Y2R^[@R50]^ antibodies have been shown to not react in knockout mice. All immunohistochemistry was performed and quantified by experimenters blind to the experimental conditions of the subjects.

We examined NPY--IR across the light cycle using previously described immunohistochemical methods^[@R36]^. All incubations were carried out at room temperature and with gentle agitation. Slices were first rinsed in PBS three times for 10 min, incubated in 50% methanol for 30 min and then 3% hydrogen peroxide for 5 min to quench endogenous peroxidases, and then rinsed in PBS three more times. Slices were incubated in PBS containing 0.5% Triton X--100 for 30 min, rinsed with PBS, and incubated in a blocking solution of PBS containing 0.1% Triton X-100 and 10% normal donkey serum for 60 min. Slices were then directly transferred to the blocking solution also containing a 1:1,250 concentration of anti-NPY made in rabbit (Abcam catalog \#ab10980, Cambridge, UK) overnight. Slices were rinsed with PBS three times, incubated in a secondary solution containing anti-rabbit Alexa Fluor 488 made in donkey (Jackson ImmunoResearch Laboratories, catalog \#711-545-152, West Grove, PA) in PBS for 2 hrs, and rinsed in PBS four times. Slices were mounted onto glass slides, allowed to dry, coverslipped with VectaShield (Vector Labs, Burlingame, CA), and stored in the dark at 4 °C.

We also examined protein expression of NPY, Y1R, and Y2R after binge alcohol drinking. Immunhistochemical protocols were carried out as previously described^[@R20],\ [@R36]^. For Y1R--IR, slices were rinsed in PBS, blocked in 10% goat serum and 0.1% Triton-X-100 in PBS for 1 h, and then transferred to PBS containing a 1:25,000 concentration of anti-Y1R made in rabbit for 72 h at 4 °C (antibody 96106 raised against NPY Y1R was provided by CURE/Digestive Disease Research Center, Antibody/RIA Core, Los Angeles, CA). After primary incubation, slices were rinsed in PBS and processed with Vectastain ABC Elite Kits (Vector Labs, Burlingame, CA) as per manufacturer's instructions. Sections were visualized by a reaction with 3,3′--diamino--benzidine (DAB, Polysciences Inc, catalog \#04001, Warrington, PA) in a reaction solution containing 0.05% DAB, 0.005% cobalt, 0.007% nickel ammonium sulfate, and 0.006% hydrogen peroxide.

For Y2R--IR, slices were incubated in primary solution containing 0.3% Triton X--100, 0.5% bovine serum albumin, and a 1:3,000 concentration of anti-Y2R (Neuromics, catalog \#RA14112, Edina, MN) for 24 hrs at 4°C. Slices were washed in TNT buffer solution containing Tris/HCl, NaCl, and Tween20 for 10 minutes followed by TNB blocking solution containing TNT buffer with 0.5% blocking reagent provided in the TSA kit for 30 minutes. Slices were washed in TNB solution containing horseradish peroxidase (1:200) for 30 minutes and rinsed in TNT buffer. Sections were incubated in Cy3 (1:50) in amplification diluents provided in the TSA kit for 10 minutes and then rinsed in TNT buffer. All slices were mounted onto glass slides, allowed to dry, coverslipped with VectaShield, and stored in the dark at 4 °C.

Images of the BNST from were obtained using a Nikon E400 microscope with a Nikon Digital Sight DS-U1 digital camera with Nikon-provided software or an Olympus FV1000 inverted confocal microscope and Olympus FluoView Software. IR intensity was analyzed by a researcher blind to conditions using Image J Software (Image J, National Institute of Health, Bethesda, MD) by calculating the percentage of the total area studied that showed staining relative to subthreshold background. For each mouse, values obtained for each slice were averaged to produce one value per mouse.

Statistical analysis {#S20}
--------------------

All data collection and analysis occurred by experimenters blind to the experimental conditions of the subjects, which were randomly or pseudo-randomly assigned to treatment groups as described in each section. Raw and baseline values for all data sets were tested for normal distribution and equal variances. Appropriate parametric statistical analyses were performed in GraphPad Prism when assumptions of normal distribution and equal variances were met; corrections for unequal variances, particularly Welch's correction, were used when necessary. Differences between control and experimental groups in behavioral pharmacology experiments were evaluated with unpaired t-tests. Behavioral effects of activation of DREADD viruses were analyzed using 2 x 2 repeated measures ANOVAs (control vs. DREADD vector, baseline vs. CNO as a repeated measure), with direct post-hoc Sidak's multiple comparisons t-tests when ANOVA interactions were significant. Effects of drugs during electrophysiological recordings were evaluated via paired t-tests between average values for each cell during baseline and washout periods, defined as the 6 min prior to and after the 10 min drug application. No statistical methods were used to predetermine sample sizes but our sample sizes are consistent with those previously published by our and other labs in the field^[@R13],\ [@R20],\ [@R36]^. All values given for electrophysiological measures, IR, and drug effects were normally distributed and are presented as mean ± S.E.M.
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![Activation of G~i~-coupled Y1R in the BNST reduces binge ethanol drinking and enhances GABAergic transmission via a PKA-dependent, postsynaptic insertion of GABA~A~ receptors. **(a)** Experimental timeline for examination of bilateral intra-BNST infusions of the Y1R agonist LeuPro NPY (99 pmol/200 nL/side, N = 7 mice) or control vehicle (CON; 200 nL/side, N = 7 mice) on EtOH DID, open field test (OF), and sucrose DID. **(b**--**f)** All statistical comparisons were made using unpaired t-tests. Mice that received infusions of LeuPro NPY consumed significantly less ethanol than CON mice during the first 2--hr epoch (**b**; t(12) = 2.59, \*p = 0.024) but not the second 2--hr epoch (**c**; p \> 0.85) of ethanol DID, but LeuPro NPY infusion did not alter measures of anxiety and locomotion in the open field test (OF), including the percent time spent in the center (**d**) and total distance traveled (**e**) of the OF, or sucrose consumption in sucrose DID (**f**; p's \> 0.45). **(g**--**h)** Representative traces of miniature inhibitory postsynaptic currents (mIPSCs; **g**) and excitatory postsynaptic currents (mEPSCs; **h**) in BNST neurons before and after 10 min bath application of LeuPro NPY (300 nM), and basal frequency and amplitude for neurons used in mPSC experiments. **(i)** LeuPro NPY increased mIPSC frequency (20.9 ± 6.1%; paired t-test baseline vs. washout: t(12) = 3.42, p = 0.005; n = 13 neurons, N = 11 mice) but did not alter mIPSC amplitude (p \> 0.20). **(j)** Conversely, LeuPro NPY produced a small decrease in the amplitude of mEPSCs (−6.9 ± 2.3%; paired t-test: t(4) = 2.99, p = 0.041; n = 5, N = 3) but did not alter mEPSC frequency (p \> 0.60). **(k)** Inclusion of GDPβS (1 mM; n = 7, N = 4) to block postsynaptic GPCR activity, NEM (50 μM; n = 5, N = 3) to block Gi signaling, PKI (20 μM; n = 6, N = 3) to block PKA signaling, and BFA (200 nM; n = 5, N = 4) to prevent receptor trafficking to the membrane all blocked the ability of bath-applied LeuPro NPY to increase mIPSC frequency (paired t-tests baseline vs. washout: p's \> 0.10), while BAPTA (10 μM; t(5) = 3.12, \*p = 0.026; n = 6, N = 5) to block calcium and DIP (2mM; t(5) = 4.76, \*\*p = 0.005; n = 6, N = 3) to block receptor endocytosis did not. LeuPro NPY decreased mIPSC amplitude only when DIP was in the intracellular solution (DIP: paired t-test: t(5) = 3.60, \*p = 0.016; others: p's \> 0.05). **(l)** LeuPro NPY (300 nM) increased the amplitude of the GABA~A~R-mediated current in response to picospritzed GABA (100 μM) by 25.3 ± 7.0%; paired t-test baseline vs. washout: (t(8) = 3.59, p = 0.007; n = 9, N = 7); inset: representative traces illustrating the effect of LeuPro NPY and complete ablation of the postsynaptic current by the GABA~A~R blocker GABAzine (20 μM). All data in **b**--**l** are presented as mean ± SEM.](nihms663797f1){#F1}

![Circadian regulation of receptor-specific NPY modulation of GABAergic transmission in the BNST**. (a)** Sample images representing mean NPY--IR in the BNST of mice sacrificed three hr into the light or dark phase of the light cycle (scale bars = 150 μM). Images shown were replicated for each individual data point shown in **b. (b)** Mean NPY--IR per mouse from five coronal slices (as in panel **a**) was not different between the light and dark phases of the light cycle (unpaired t-test: p \> 0.40; N's = 10/group). **(c**--**d)** Basal sIPSC and mIPSC frequency (**c**) and amplitude (**d**) were not different across the light cycle (unpaired t-tests: p's \> 0.15; CON n = 13, N = 7, EtOH n = 13, N = 7). **(e)** Bath application of LeuPro NPY (300 nM) increased, while the Y2R agonist NPY 13--36 (300 nM) decreased, mIPSC frequency during the light phase (LeuPro NPY: as shown in [Fig. 1i](#F1){ref-type="fig"}, \*\*p = 0.005; NPY 13--36: paired t-test baseline vs. washout: t(5) = 3.57, \*p = 0.016, n = 6, N = 5) but not the dark phase (p's \> 0.15; LeuPro n = 5, N = 4, NPY 13--36 n = 6, N = 4), of the light cycle. **(f)** Bath application of the Y1R antagonist BIBP 3226 (1 μM; n = 11, N = 10) or the Y2R antagonist BIIE 0246 (1 μM; n = 4, N = 3) did not alter mIPSC frequency during the light phase (paired t-tests baseline vs. washout: p's \> 0.20); BIIE 0246 increased mIPSC frequency during the dark phase (t(3) = 8.45, \*\*p = 0.004; n = 4, N = 3), while BIBP 3226 did not (p \> 0.15; n = 5, N = 4). All data in **b**--**l** are presented as mean ± SEM.](nihms663797f2){#F2}

![Chronic binge alcohol drinking alters receptor-specific NPY modulation of GABAergic transmission in the BNST of mice and monkeys. **(a)** Experimental timeline for 3-cycle DID in mice. **(b)** BNST neurons from mice that drank ethanol (EtOH) had higher sIPSC frequency than water-drinking controls (CONs; unpaired t-test with Welch's correction: t(11) = 2.32, \*p = 0.040, CON n = 8, N = 5, EtOH n = 12, N = 5), but mIPSC frequency did not differ between groups (unpaired t-test: p \> 0.95; CON n = 15, N= 7, EtOH n = 12, N = 6). **(c)** LeuPro NPY (300 nM) significantly increased mIPSC frequency in EtOH mice (paired t-test baseline vs. washout: t(5) = 3.58, p = 0.016; n = 6, N = 6) but not CONs (p \> 0.60, n = 7, N = 7). **(d)** NPY 13--36 (300 nM) decreased mIPSC frequency in ethanol-drinking mice (t(5) = 2.97, p = 0.031; n = 6, N = 5) but not controls (p \> 0.85, n = 7, N = 6). **(e**--**g)** Mean NPY-IR (average IR from 3--5 slices per mouse) was similar between groups (**e**; unpaired t-test: p \> 0.75; CON N = 10, EtOH N = 7), but Y1R--IR (**f**; t(13) = 4.23, \*\*\*p = 0.001; CON N = 9, EtOH N = 6) and Y2R-IR (**g**; t(15) = 2.50, \*p = 0.025; CON N = 10, EtOH N = 7) were higher in the BNST of EtOH mice than CONs. **(h)** NPY-IR was significantly decreased in the BNST of EtOH mice compared to water-drinking CONs immediately after the last binge ethanol drinking exposure in 1-cycle and 3-cycle DID (N's = 10/group), but was not different between one and 3-cycle DID (one-way ANOVA: F(2,27) = 14.25, p \< 0.0001; post-hoc Sidak's multiple comparisons test: CON vs. 1-cycle: t(18) = 3.58,\*\* p = 0.004; CON vs. 3-cycle DID: t(18) = 5.22, \*\*\*p \< 0.001; 1-cycle DID vs. 3-cycle DID: p \> 0.25), suggesting that NPY was similarly recruited acutely during each binge ethanol session across each cycle. **(i)** Experimental timeline for voluntary ethanol self-administration (ESA; access to 4% ethanol for 22 h/d, 7 d/wk for 12 mo) in adult male rhesus monkeys. **(j)** Representative traces of mIPSCs from ethanol self-administering rhesus monkey BNST neurons before and after bath application of LeuPro NPY (300 nM). **(k)** mIPSC frequency was unaltered by LeuPro NPY following one cycle of DID in EtOH mice (n = 8, N = 4) and water-drinking CONs (n = 5, N = 3; paired t-tests baseline vs. washout: p's \> 0.30), but it was increased in EtOH, but not CON, mice 1 d after the final binge session of 3-cycle EtOH DID, as shown in **c**, which could be blocked by intracellular inclusion of PKI (20 μM; p \> 0.35; n = 3, N = 2). The adaptation in LeuPro NPY modulation of mIPSC frequency was still present 10 d after the final binge ethanol session in EtOH mice (t(5) = 3.09, \*p = 0.027; n = 6, N = 3) but not CONs (p \> 0.50, n = 5, N = 3) and was also observed in rhesus monkeys after 12 mo of continuous access to ethanol (t(8) = 4.21, \*\*p = 0.003; n = 9, N = 5) but not control solution (p \> 0.50; n = 4, N = 3). All data in **b**--**h** and **k** are presented as mean ± SEM.](nihms663797f3){#F3}

![Y1R-mediated effects on inhibition in the BNST are specific to CRF neurons. **(a)** Sample image of the dorsal BNST in a naïve *CRF--Cre* x Ai3 reporter mouse taken from a coronal brain slice depicting *CRF--Cre*-positive neurons in green (scale bar = 150 μM). Fluorescence expression shown is typical in this mouse line and was confirmed for all mice used in experiments for panels **b**--**h. (b)** Representative traces of mIPSCs from *CRF--Cre*-positive (CRF+) and *CRF--Cre*-negative (CRF−) neurons in the BNST before and after bath application of LeuPro NPY (300 nM). **(c**--**d)** Basal mIPSC frequency did not differ in CRF+ and CRF− BNST neurons (unpaired t-test: p \> 0.20; CRF+ n = 11, N = 6, CRF− n = 7, N = 4 for all panels), but basal mIPSC amplitude was greater in CRF+ than CRF− neurons (t(16) = 2.25,\*p = 0.039). **(e)** Bath application of LeuPro NPY increased mIPSC frequency in CRF+ neurons in the BNST by 54.7 ± 19.3% (paired t-test baseline vs. washout: t(10) = 2.83, \*p = 0.018) but did not alter mIPSC frequency in CRF− neurons (−1.3 ± 7.8%; p \> 0.85; magnitude of average percent change in frequency depicted in inset bar graph). **(f)** LeuPro NPY slightly but significantly decreased mIPSC amplitude in CRF+ neurons (−12.4 ± 5.2%; t(10) = 2.40, \*p = 0.038) but did not alter mIPSC amplitude in CRF− neurons (−0.1 ± 4.2%; p \> 0.95; magnitude of effects depicted in inset bar graph). **(g)** Representative averaged traces (top) and weighted tau values (bottom) of CRF+ and CRF− neurons in the BNST before and after bath application of LeuPro NPY showing that LeuPro NPY increased the decay magnitude of mIPSCs in CRF+ neurons (paired t-test: t(10) = 2.40, \*p = 0.037) but did not alter the decay of mIPSC events in CRF− neurons (p \> 0.50); rise time of mIPSCs was not altered in either group (p's \> 0.10, data not shown). **(h)** Cumulative probability distributions of mIPSC amplitude showing that there was a leftward shift in the distribution by the 75^th^ percentile of events in CRF+ neurons (paired t-test: t(10) = 2.34, \*p = 0.041), indicating that application of LeuPro NPY led to a greater number of mIPSC with smaller amplitude, while there was no effect on the distribution of mIPSC amplitude in CRF− neurons (p's \> 0.45). All data in **c**--**h** are presented as mean ± SEM.](nihms663797f4){#F4}

![Direct *in vivo* chemogenetic activation of G~i~ signaling in BNST CRF neurons recapitulates, while chemogenetic activation of G~s~ signaling blocks, the effect of Y1R activation on binge ethanol consumption. **(a)** Experimental timeline for examination of behavioral effects of *in vivo* DREADD activation of G~i~ signaling in BNST CRF neurons in CRF-Cre mice (vehicle = white arrows, CNO (3 mg/kg) = green arrows). **(b)** Representative image of a coronal slice containing BNST from a *CRF-Cre* mouse following microinjection of the AAV8-hSyn-DIO-hM4D-mCherry (G~i~-DREADD) into the BNST and behavioral testing described in panel **a** (scale bar = 50 μm). Similar expression was confirmed for all mice in **c**--**e. (c)** CNO administration produced a decrease in binge ethanol consumption in DID compared to baseline in *CRF-Cre* mice with the G~i~-DREADD (N = 11 for panels **b**--**e**) but not the control vector AAV8-hSyn-DIO-mCherry (CON; N = 12 for panels **b**--**e**), in the BNST (2×2 repeated measures ANOVA: main effect of CNO (F(1,21) = 29.8, p \< 0.0001) and significant interaction between G~i~-DREADD condition and CNO (F(1,21) = 7.27, p = 0.014); post-hoc t-tests: significant difference between baseline and CNO for the G~i~-DREADD mice (t(10) = 6.24, \*\*\*p \< 0.0001) but not the CON vector mice (p \> 0.10)). **(d)** CNO administration produced an increase in the percent time spent in the center of the OF in *CRF-Cre* mice with the G~i~-DREADD, but not the control vector, in the BNST (2×2 repeated measures ANOVA: significant interaction between G~i~-DREADD condition and CNO (F(1,21) = 4.48, p = 0.047); post-hoc t-test: significant difference between baseline and CNO for the G~i~-DREADD mice (t(10) = 3.15, \*p = 0.010) but not the CON vector mice (p \> 0.65)). **(e)** G~i~-DREADD and CON mice did not differ in their locomotor behavior (unpaired t-test: p \> 0.50). **(f)** Experimental timeline for examination of behavioral effects of *in vivo* DREADD activation of G~s~ signaling in BNST CRF neurons in *CRF-Cre* mice and interaction between Gs-DREADD and LeuPro NPY (vehicle = white arrows, CNO (3 mg/kg) = purple arrows, LeuPro NPY (99 pmol/200 nL/side) = blue arrows). **(g)** Representative image showing expression of the AAV8-hSyn-DIO-rM3D-mCherry (G~s~-DREADD) in the BNST of a *CRF-Cre* mouse that underwent behavioral testing (scale bar = 50 μm). Similar expression was confirmed for all mice in **h**--**k. (h)** CNO administration did not alter binge ethanol consumption in either the CON (N = 12) or G~s~-DREADD (N = 7) groups (2 x 2 repeated measures ANOVA: p's \> 0.15). **i**--**j**) While there was a main effect of CNO in the percent time spent in the center of the OF with a 2 x 2 repeated measures ANOVA (**i**; F(1,17) = 9.92, p = 0.006), there was no main effect of DREADD group or interaction (p's \> 0.50), and there was no difference between CON and G~s~-DREADD mice in locomotor behavior (**j**; unpaired t-test: p \> 0.70). **(k)** Activation of the G~s~-DREADD blocked the Y1R-mediated suppression of drinking (unpaired t-test: t(12) = 2.36, \*p = 0.036; CON N = 9, G~s~-DREADD N = 5), suggesting that activation of PKA signaling is sufficient to prevent the behavioral effect of Y1R-mediated inhibition of PKA signaling. Data in **e**, **j**, and **k** are presented as mean ± SEM.](nihms663797f5){#F5}
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